- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00636298
Study of Cetuximab and Bevacizumab in Cancer of the Esophagus After Failure of Patient's First Therapy
Phase II Study of Cetuximab and Bevacizumab in Esophageal Carcinoma That Failed First Line Therapy
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Cancer of the esophagus often has a poor outcome since many patients have advanced disease when they are diagnosed. The average survival rate after five years has increased from 4% in the 1970s to around 14% currently.
Surgery to remove the tumor or treatment with radiotherapy alone has led to disappointing results for patients. Chemotherapy has some activity in patients with advanced disease, although responses are usually short. New strategies are trying to combine these three treatment approaches to improve survival for these patients.
This study will test the combination of cetuximab and bevacizumab in patients with locally advanced esophageal cancer. This is a group of patients with usually poor outcomes from treatment with surgery, radiotherapy or chemotherapy alone. Scientifically, this study will help assess the value in combining these two different types of drug.
Tipo de estudo
Estágio
- Fase 2
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Patients must have histologically or cytologically confirmed squamous cell carcinoma or esophageal adenocarcinoma.
- The disease must be recurrent after first line systemic therapy, with or without radiation, with or without surgery.
- Patients must be at least 1 month from prior chemotherapy or radiation therapy.
- ECOG performance status ≤ 1 (Karnofsky > 60%)
- Life expectancy of greater than 12 weeks.
- Age > 18.
Patients must have normal bone marrow and other organ function or defined below:
- Absolute neutrophil count, > 1, 500/μL
Platelet counts, > 100, 00/μL
_ Hemoglobin, > 8.0 gm/dL-
- Creatinine(< 1.5mg/dL)
- No significant intercurrent medical illness (including NYHA class II, III or IV heart disease, significant arrhythmias requiring medication, symptomatic coronary artery disease, myocardial infarction within the previous 6 months.
- Women of childbearing potential must have a negative pregnancy test.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
I. Disease-specific Exclusions
- All histologic types other than squamous cell carcinoma or adenocarcinoma.
- Patients currently receiving other investigational agents, or who have received cetuximab previously.
- Patients with known brain metastases.
- History of severe allergic reactions attributed to compounds of similar chemical or biologic composition to Cetuximab or Bevacizumab.
- Patients with history of any other malignancy (except non-melanomatous skin cancer or CIS of cervix) are ineligible unless a period of 5 years has lapsed since treatment of the previous cancer and the patient has remained continuously disease free.
- Patients who are felt to be poorly compliant.
- Women who are breast-feeding.
II. General Medical Exclusions
Subjects meeting any of the following criteria are ineligible for study entry:
- Inability to comply with study and/or follow-up procedures.
- Life expectancy of less than 12 weeks.
- Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study.
III. Bevacizumab-Specific Exclusions
- Inadequately controlled hypertension (defined as systolic blood pressure >150 and/or diastolic blood pressure >100 mmHg on antihypertensive medications).
- Any prior history of hypertensive crisis or hypertensive encephalopathy.
- New York Heart Association (NYHA) Grade II or greater congestive heart failure
- History of myocardial infarction or unstable angina within 6 months prior to study enrollment.
- History of stroke or transient ischemic attack within 6 months prior to study enrollment.
- Known CNS disease.
- Significant vascular disease (e.g., aortic aneurysm, aortic dissection).
- Symptomatic peripheral vascular disease.
- Evidence of bleeding diathesis or coagulopathy.
- Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to study enrollment or anticipation of need for major surgical procedure during the course of the study.
- Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to study enrollment.
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to study enrollment.
- Serious, non-healing wound, ulcer, or bone fracture.
Proteinuria at screening as demonstrated by either
- Urine protein: creatinine (UPC) ratio ≥ 1.0 at screening OR
- Urine dipstick for proteinuria ≥ 2+ (patients discovered to have ≥ 2+ proteinuria on dipstick urinalysis at baseline should undergo a 24 hour urine collection and must demonstrate ≤ 1g of protein in 24 hours to be eligible)
- Known hypersensitivity to any component of bevacizumab.
- Pregnant (positive pregnancy test) or lactating. Use of effective means of contraception (men and women) in subjects of child-bearing potential.
- History of myocardial infarction or unstable angina within 6 months of study enrollment.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: A
Single arm treatment with combination of cetuximab and bevacizumab
|
Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly Bevacizumab - 10 mg/kg every 2 weeks |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Prazo |
---|---|
Progression-free survival
Prazo: Every 3 months
|
Every 3 months
|
Medidas de resultados secundários
Medida de resultado |
Prazo |
---|---|
Response rate
Prazo: Every 3 months
|
Every 3 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Nabil Saba, MD, Emory University Winship Cancer Institute
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças do aparelho digestivo
- Neoplasias por Tipo Histológico
- Neoplasias
- Neoplasias por local
- Neoplasias Glandulares e Epiteliais
- Neoplasias gastrointestinais
- Neoplasias do Aparelho Digestivo
- Doenças Gastrointestinais
- Neoplasias de Cabeça e Pescoço
- Doenças Esofágicas
- Carcinoma
- Neoplasias Esofágicas
- Efeitos Fisiológicos das Drogas
- Agentes Antineoplásicos
- Agentes Antineoplásicos Imunológicos
- Inibidores de angiogênese
- Agentes Moduladores da Angiogênese
- Substâncias de crescimento
- Inibidores de crescimento
- Bevacizumabe
- Cetuximabe
Outros números de identificação do estudo
- IRB00006037
- 6037 (Outro identificador: Other)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Carcinoma Esofágico
-
Novartis PharmaceuticalsAtivo, não recrutandoAdvanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal Squamous CellCancer (SCC),Head/Pneck SCC,MelanomaTaiwan, Estados Unidos, Holanda, Espanha, Republica da Coréia, Itália, Japão, Canadá, Cingapura
Ensaios clínicos em Bevacizumab, cetuximab
-
Istituto Scientifico Romagnolo per lo Studio e...ConcluídoCâncer Colorretal MetastáticoItália
-
Spanish Cooperative Group for the Treatment of...Concluído
-
Assistance Publique - Hôpitaux de ParisGERCOR - Multidisciplinary Oncology Cooperative GroupConcluídoCâncer de Esôfago Estágio IIIFrança
-
St. Luke's-Roosevelt Hospital CenterBristol-Myers SquibbRescindidoCancer de coloEstados Unidos
-
Hospital Universitari de BellvitgeInstituto de Salud Carlos IIIRescindidoCâncer de cólon | Metástase irressecável originária de câncer de cólonEspanha
-
Centre Hospitalier Universitaire de NiceRescindido
-
Glycotope GmbHConcluídoTumor Sólido, AdultoAlemanha, Itália, Espanha
-
Neon HospitalOndokuz Mayıs UniversityConcluídoEdema macular diabético
-
Cancer Institute and Hospital, Chinese Academy...Ainda não está recrutando
-
West China HospitalRecrutamentoNeoplasia do EstômagoChina